Who is sponsoring NCT07299292?

NCT07299292 is sponsored by SMED Clinical Research.

What drugs are being tested in NCT07299292?

Interventions in NCT07299292: Abiraterone 250 mg with food + prednisone.

What condition does NCT07299292 study?

NCT07299292 studies Prostate Cancer (Diagnosis).

Is NCT07299292 still recruiting?

NCT07299292 is currently recruiting now. Last updated 23 December 2025.

Last reviewed 2025-12-23 · How we verify

NCT07299292

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

Recruiting now Phase 2 Last updated 23 December 2025

What this trial tests

Phase 2 trial testing Abiraterone 250 mg with food + prednisone in Prostate Cancer (Diagnosis) in 60 participants. Currently enrolling.

Timeline

1 December 2025

Primary endpoint
31 December 2026

30 March 2027

Quick facts

Lead sponsor	SMED Clinical Research
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 December 2025
Primary completion	31 December 2026
Estimated completion	30 March 2027
Sites	3 locations across Argentina, Spain

Drugs / interventions tested

Abiraterone 250 mg with food + prednisone — full drug profile →

Conditions studied

Prostate Cancer (Diagnosis) — all drugs for Prostate Cancer (Diagnosis) →

Sponsor

SMED Clinical Research

Who can join

18 and older, male only, with Prostate Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypothesis The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer (Diagnosis)

Currently open trials in the same condition.

NCT07144228 — Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer · recruiting
NCT07398690 — INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis · NA · recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting
NCT07369570 — Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging · NA · recruiting
NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07299292 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SMED Clinical Research
Last refreshed: 23 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07299292.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing